NAGE — Niagen Bioscience Inc

Niagen Bioscience, Inc. (NAGE) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 Revenue: $33.8 million, up 16% year-over-year.
• Full Year Revenue: $129.4 million, a 30% increase year-over-year, exceeding initial guidance of 18%.
• Net Income: Q4 net income was $4.1 million; full year net income reached $17.4 million, compared to $8.6 million in 2024.
• Cash Position: Ended 2025 with $64.8 million in cash and no debt.
• Gross Margin: Improved to 64.3% for the full year, with Q4 gross margin at 64.1%.

2. Strategic Updates and Business Highlights

• Product Development: Launched Niagen Plus and secured a patent for intravenous and injectable formulations, with plans to introduce at-home injection kits in 2026.
• Market Expansion: Present in over 1,200 health clinics; plans to expand into beauty and cosmetics markets with new topical products.
• Scientific Leadership: Continued to publish research supporting the benefits of nicotinamide riboside (NR), with 29 studies published since the last earnings call.
• Divestiture: Sold the ChromaDex Reference Standards business for $6 million to streamline operations and focus on core NAD science.

3. Forward Guidance and Outlook

• 2026 Revenue Growth: Projected growth of 10% to 15% year-over-year, excluding revenue from the divested segment.
• Gross Margin: Slight improvement expected due to better supply chain efficiencies.
• Expense Management: Selling and marketing expenses anticipated to increase in absolute terms but remain stable as a percentage of sales. R&D expenses will also rise due to investments in pharmaceutical development.
• Share Repurchase: $10 million buyback program initiated, with $250,000 utilized to date.

4. Bad News, Challenges, or Points of Concern

• Increased Competition: Notable competition in the NAD space, particularly from NMN products following a recent FDA ruling, which may impact market share.
• Regulatory Risks: Ongoing litigation against the FDA regarding NMN products, with potential implications for market dynamics.
• Operational Challenges: General and administrative expenses rose significantly due to increased employee-related costs and stock-based compensation.

5. Notable Q&A Insights

• Injection Products: Initial launch will feature one SKU targeting the biohacker community, with plans to expand offerings based on market response.
• Cautious Guidance: Management emphasized conservative revenue guidance for 2026, reflecting a desire to avoid overpromising.
• Growth Drivers: Anticipated growth from existing products, new IV and injection products, and increased brand awareness through strategic marketing efforts.
• Legal Expenses: Management does not expect significant costs from the ongoing lawsuit against the FDA, suggesting it will not materially impact overall legal expenses for 2026.

This summary encapsulates the key points from Niagen Bioscience's Q4 2025 earnings call, highlighting financial performance, strategic initiatives, outlook, challenges, and insights from the Q&A session.